Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Selectis Health (GBCS) EBIT (2017 - 2025)

Selectis Health's EBIT history spans 14 years, with the latest figure at -$296960.0 for Q3 2025.

  • For Q3 2025, EBIT rose 74.66% year-over-year to -$296960.0; the TTM value through Sep 2025 reached -$1.3 million, up 77.49%, while the annual FY2024 figure was -$2.7 million, 69.54% up from the prior year.
  • EBIT for Q3 2025 was -$296960.0 at Selectis Health, up from -$450289.0 in the prior quarter.
  • Across five years, EBIT topped out at $1.3 million in Q2 2022 and bottomed at -$3.0 million in Q4 2023.
  • The 5-year median for EBIT is -$696264.0 (2024), against an average of -$730219.9.
  • The largest annual shift saw EBIT crashed 790.66% in 2021 before it surged 63964.52% in 2022.
  • A 5-year view of EBIT shows it stood at -$1.2 million in 2021, then dropped by 23.25% to -$1.4 million in 2022, then plummeted by 108.95% to -$3.0 million in 2023, then soared by 96.75% to -$97261.0 in 2024, then plummeted by 205.32% to -$296960.0 in 2025.
  • Per Business Quant, the three most recent readings for GBCS's EBIT are -$296960.0 (Q3 2025), -$450289.0 (Q2 2025), and -$421746.0 (Q1 2025).